PPC 5650

Drug Profile

PPC 5650

Alternative Names: PPC-5650

Latest Information Update: 24 Mar 2016

Price : $50

At a glance

  • Originator Aros Pharma; PainCeptor Pharma Corporation
  • Developer Aros Pharma
  • Class Small molecules
  • Mechanism of Action ASIC1a channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 01 May 2013 Aros Pharma completes a phase I trial for Pain in Sweden (NCT01449487)
  • 19 Jan 2012 Aros Pharma initiates enrolment in a phase I trial for Pain in Sweden (NCT01449487)
  • 10 Sep 2008 Pharmacodynamics data from a phase I trial in Pain released by PainCeptor Pharma Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top